<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Promoter CpG island hypermethylation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes is a common hallmark of <z:hpo ids='HP_0000001'>all</z:hpo> human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Many researchers have been looking for potential epigenetic therapeutic targets in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> using gene expression profiling with DNA microarray approaches </plain></SENT>
<SENT sid="2" pm="."><plain>Our recent genome-wide platform of CpG island hypermethylation and gene expression in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cell lines revealed that FBN2 and TCERG1L gene silencing is associated with DNA hypermethylation of a CpG island in the promoter region </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, promoter DNA hypermethylation of FBN2 and TCERG1L in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> occurs as an early and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific event in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Both genes showed high frequency of methylation in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines (&gt;80% for both of genes), <z:mpath ids='MPATH_270'>adenomas</z:mpath> (77% for FBN2, 90% for TCERG1L, n = 39), and <z:mp ids='MP_0002038'>carcinomas</z:mp> (86% for FBN2, 99% for TCERG1L, n = 124) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="17137">Bisulfite</z:chebi> sequencing confirmed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific methylation of FBN2 and TCERG1L of promoters in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell line and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> but not in <z:mpath ids='MPATH_458'>normal</z:mpath> colon </plain></SENT>
<SENT sid="6" pm="."><plain>Methylation of FBN2 and TCERG1L is accompanied by downregulation in cell lines and in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> as described in the Oncomineâ„¢ website </plain></SENT>
<SENT sid="7" pm="."><plain>Together, our results suggest that gene silencing of FBN2 and TCERG1L is associated with promoter DNA hypermethylation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and may be excellent biomarkers for the early detection of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>